181289-10-1 Usage
General Description
(2R)-2-[(ethoxycarbonyl)methyl]-4-methylpentanoic acid, also known as ethyl (2R)-2-[(ethoxycarbonyl)methyl]-4-methylpentanoate, is a chemical compound with the molecular formula C11H20O4. It is an ester derivative of (2R)-2-acetoxymethyl-4-methylpentanoic acid and is commonly used in the pharmaceutical and chemical industries. (2R)-2-[(ethoxycarbonyl)methyl]-4-methylpentanoic acid has a variety of applications, including as an intermediate in the synthesis of pharmaceuticals and as a building block in organic synthesis. It is also used in the development of various drugs and in the production of fine chemicals. As a versatile compound, (2R)-2-[(ethoxycarbonyl)methyl]-4-methylpentanoic acid has a wide range of potential uses in different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 181289-10-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,2,8 and 9 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 181289-10:
(8*1)+(7*8)+(6*1)+(5*2)+(4*8)+(3*9)+(2*1)+(1*0)=141
141 % 10 = 1
So 181289-10-1 is a valid CAS Registry Number.
181289-10-1Relevant articles and documents
Enzymatic preparation of homochiral 2-isobutyl succinic acid derivatives
Wirz, Beat,Soukup, Milan
, p. 187 - 189 (1997)
An efficient enzymatic procedure for the enantio- and regioselective monohydrolysis of diethyl 2-isobutyl succinate 3 using subtilisin Carlsberg has been developed. The product (R)-2-isobutyl succinic acid 4-ethyl ester 4, a collagenase inhibitor building block, was obtained in high enantiomeric excess (> 99%) and yield (> 45%). Similarly, (R)-2-isobutyl succinic acid 4-nitrile 2 was produced in 98% ee from its ethyl ester 1.
INHIBITORS OF ANTHRAX LETHAL FACTOR
-
, (2008/06/13)
Methods, compounds and compositions for preventing and treating anthrax infections by inhibiting Anthrax Lethal Factor (LF) activity.
Hydroxamic acid based collagenase inhibitors
-
, (2008/06/13)
This disclosure relates to a novel class of hydroxamic acid based collagenase inhibitor derivatives. The disclosure further relates to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions in the treatment
